or Try an Advanced Search...

    Rare Neurological Disorders Stocks List

    Symbol Grade Name % Change
    HRMY B Harmony Biosciences Holdings, Inc. -1.23
    OVID F Ovid Therapeutics Inc. -1.95
    SILO B Silo Pharma, Inc. -1.62
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Neurological Disorders Urological Disorders Alzheimer's Disease Anticonvulsants Biopharmaceutical Chloroarenes Depression Disorders Epilepsy Ethers Fragile X Syndrome Genodermatoses Narcolepsy Organ Systems Parkinson's Disease Pharmaceutical Piperidines Post Traumatic Stress Disorder Sedatives Stage Pharmaceutical

    Related ETFs - A few ETFs which own one or more of the above listed Rare Neurological Disorders stocks.

    Symbol Grade Name Weight
    BBP C BioShares Biotechnology Products Fund 1.81
    JSML C Janus Small Cap Growth Alpha ETF 1.6
    XPH C SPDR S&P Pharmaceuticals ETF 1.17
    SIXS B 6 Meridian Small Cap Equity ETF 1.06
    PILL D Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF 0.99
    View all Rare Neurological Disorders ETFs...
    Compare ETFs
    Compare BBP to SIXS Compare JSML to SIXS Compare XPH to PILL

        Rare Neurological Disorders Stocks Recent News

        Date Stock Title
        May 3 HRMY Harmony Biosciences Holdings First Quarter 2024 Earnings: EPS Beats Expectations
        May 2 HRMY Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences is a Solid Choice
        May 1 HRMY Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
        May 1 HRMY HRMY or TECH: Which Is the Better Value Stock Right Now?
        May 1 HRMY Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript
        May 1 OVID Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
        Apr 30 HRMY Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
        Apr 30 HRMY Harmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade)
        Apr 30 HRMY Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript
        Apr 30 HRMY Harmony Biosciences Holdings, Inc. 2024 Q1 - Results - Earnings Call Presentation
        Apr 30 HRMY Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
        Apr 30 HRMY Harmony Biosciences Exceeds Analyst Revenue Forecasts While Aligning with EPS Projections in Q1 2024
        Apr 30 HRMY Harmony Biosciences acquires Epygenix gaining rare epilepsy pipeline
        Apr 30 HRMY Harmony Biosciences Non-GAAP EPS of $0.88 beats by $0.10, revenue of $154.6M misses by $0.19M
        Apr 30 HRMY Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
        Apr 30 HRMY Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
        Apr 29 HRMY Harmony Biosciences Q1 2024 Earnings Preview
        Related Industries: Biotechnology
        Related Stock Lists: Neurological Disorders Urological Disorders Alzheimer's Disease Anticonvulsants Biopharmaceutical Chloroarenes Depression Disorders Epilepsy Ethers Fragile X Syndrome Genodermatoses Narcolepsy Organ Systems Parkinson's Disease Pharmaceutical Piperidines Post Traumatic Stress Disorder Sedatives Stage Pharmaceutical
        Rare Neurological Disorders

        Rare neurological disorders are conditions that affect the nervous system and are not commonly seen in the general population. These disorders can affect the brain, spinal cord, peripheral nerves, and muscles. Examples of rare neurological disorders include Huntington's disease, Tourette syndrome, and muscular dystrophy.

        Browse All Tags